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Editorial

Chasing the Cardiogenic Shock Unicorn
Cardiogenic shock (CS) in the setting of acute myocardial
infarction (MI) is a deadly condition, and there has been a
search for the optimal treatment strategy for years. However,
in-hospital survival with CS has plateaued at 60% to 70%.
Several reports in the literature emphasized the need for more
scientific evidence on the optimal management of CS complicating MI. The recently published position statement by the
Acute Cardiovascular Care Association of the European Society of Cardiology has summarized the recent evidence and
provided expert consensus.1
The key points from this position statement relating to the
management of CS in the MI setting are (1) direct admission
or transfer of patients to regional centers for CS with 24-hour/
7-day percutaneous coronary intervention (PCI)/coronary
artery bypass graft/mechanical circulatory support (MCS)
availability, with the focus on risk stratification using Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK
II) score and advanced monitoring; (2) early revascularization
to reduce ischemic time either with PCI or coronary artery
bypass graft, limited to the culprit lesion, with possible staged
revascularization of other lesions when PCI is considered; (3)
use of intravenous antiplatelet agents and intravenous anticoagulants strategy in the setting of PCI; (4) catecholamines
administered at the lowest possible dose and for the shortest
possible duration, with specific preference for norepinephrine
as the vasoconstrictor of choice when blood pressure is low
and tissue perfusion is insufficient; (5) the routine use of the
intra-aortic balloon pump (IABP) is not recommended and
other MCS such as Impella, TandemHeart, and ECMO cannot
be recommended as first-line treatment in CS; the use of percutaneous MCS devices should be restricted to cases of refractory CS and relying on individual experience in dedicated
centers; (6) in patients with CS in cardiac arrest, moderate
therapeutic hypothermia (33˚C) after resuscitation should be
the targeted temperature; (7) in cases of mechanical complications, such as ventricular septal defect or acute mitral regurgitation, current ESC guidelines recommend the use of IABP;
and (8) besides the general principles of RV dysfunction management, the use of MCS devices, with dedicated RV support
or VA-ECMO, may be considered in certain patients with
refractory CS.

The most significant change is the recommendation against
routine PCI in the noninfarct-related artery, after the CULPRIT-SHOCK trial showed a significant clinical benefit of a
culprit-lesiononly strategy, with a reduction in the primary
endpoint of 30-day mortality or renal replacement therapy.2 In
addition, the newly proposed definition and 5 stages of CS by
the Society for Cardiovascular Angiography and Interventions,3 to guide identification and rapid detection/management
of CS, have provided more granularity in the management
approach to CS following acute myocardial infarction.
The concept of regional cardiogenic shock centers, which
are equipped with at least 2 catheterization laboratories with
24-hour PCI service and on-site surgery and are experienced
in the use of at least 2 MCS devices, is introduced here to coordinate and optimize the outcome of CS care. Apart from revascularization, most of the current recommendations are based
on registry data or expert opinion. Moreover, CS in MI is a
complex condition with wide diversity; hence, results from a
clinical trial might not be applicable to every CS patient. For
instance, although the IABP was shown to have no benefit in
the IABP-SHOCK trial, this device routinely is used in catheterization laboratories worldwide for different reasons/indications. The hotly anticipated DanGer trial (clinicaltrials.gov:
NCT01633502) on the MCS device Impella (Abiomed Inc.)
might not offer the answer for all CS patients. And although
success rates with percutaneous devices, such as the Impella
have not been uniform, this device is also part of the therapeutic armamentarium. Although the CS unicorn chase continues,
there must be comfort in being uncomfortable! It is technically
challenging to conduct a vigorously designed randomized controlled trial in treatment of CS MI patients, as the condition
itself is too complex to be generalized; the recruitment time
frame is narrow, along with ethical dilemmas. Yet, the field
will not move forward without venturing into the unknown.
Apart from left ventricular failure, the previously forgotten
right ventricle (RV) has started to gain attention in the management of refractory cardiogenic shock. Yet, a lot of uncertainties still exist including how to define RV failure and how
to support the RV acutely both in the operating room and catheterization suite. New percutaneous MCS, with smaller profiles (Impella ECP), with higher support power or different

https://doi.org/10.1053/j.jvca.2020.08.052
1053-0770/Ó 2020 Elsevier Inc. All rights reserved.

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by Elsevier on March 10, 2021.
For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.

Editorial / Journal of Cardiothoracic and Vascular Anesthesia 35 (2021) 366367

unloading mechanisms (Impella 5.0, TandemHeart), now are
available or under investigation. Off-label applications of percutaneous techniques or devices have been reported (eg, MitraClip in papillary muscle rupture,4 percutaneous ventricular
septal rupture closure5) to manage mechanical complications
of MI in surgically inoperable patients. MCS is not without
risk,6,7 and not every patient with CS requires MCS. The future
undoubtedly will see more advances in the technology of percutaneously placed circulatory assist devices for CS patients;
the question is, will outcomes concomitantly improve?
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